Moderna, Inc.Cambridge, Massachusetts, United States
Disclosure information not submitted.
563 - Safety and Immunogenicity of mRNA-1273.815 in COVID-19 Vaccine-Naïve Children 2 Through 4 Years of Age: Results From a Phase 3, Open-Label Trial
Wednesday, October 22, 202511:06 AM - 11:18 AM US ET
